DE60318327T2 - Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe - Google Patents

Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe Download PDF

Info

Publication number
DE60318327T2
DE60318327T2 DE60318327T DE60318327T DE60318327T2 DE 60318327 T2 DE60318327 T2 DE 60318327T2 DE 60318327 T DE60318327 T DE 60318327T DE 60318327 T DE60318327 T DE 60318327T DE 60318327 T2 DE60318327 T2 DE 60318327T2
Authority
DE
Germany
Prior art keywords
resveratrol
virus
cells
infection
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318327T
Other languages
German (de)
English (en)
Other versions
DE60318327D1 (de
Inventor
Enrico Garaci
Anna T. Palamara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60318327D1 publication Critical patent/DE60318327D1/de
Publication of DE60318327T2 publication Critical patent/DE60318327T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60318327T 2002-11-06 2003-10-14 Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe Expired - Lifetime DE60318327T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20020562 2002-11-06
IT000562A ITRM20020562A1 (it) 2002-11-06 2002-11-06 Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
PCT/IT2003/000626 WO2004041260A1 (en) 2002-11-06 2003-10-14 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections

Publications (2)

Publication Number Publication Date
DE60318327D1 DE60318327D1 (de) 2008-02-07
DE60318327T2 true DE60318327T2 (de) 2008-12-18

Family

ID=32310188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318327T Expired - Lifetime DE60318327T2 (de) 2002-11-06 2003-10-14 Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe

Country Status (18)

Country Link
US (1) US8431617B2 (https=)
EP (1) EP1567137B1 (https=)
JP (1) JP4589118B2 (https=)
KR (1) KR101060331B1 (https=)
AR (1) AR041891A1 (https=)
AT (1) ATE381929T1 (https=)
AU (1) AU2003279551A1 (https=)
CA (1) CA2504872C (https=)
CY (1) CY1107302T1 (https=)
DE (1) DE60318327T2 (https=)
DK (1) DK1567137T3 (https=)
ES (1) ES2295660T3 (https=)
IT (1) ITRM20020562A1 (https=)
MX (1) MXPA05004628A (https=)
PL (1) PL217628B1 (https=)
PT (1) PT1567137E (https=)
TW (1) TWI337863B (https=)
WO (1) WO2004041260A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951285A2 (en) * 2005-11-18 2008-08-06 Ares Trading S.A. Interferon in influenza
EP2268272A2 (en) * 2008-03-06 2011-01-05 Mount Sinai School of Medicine of New York University Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
WO2010053949A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating amp-kinase
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
KR100950445B1 (ko) 2009-10-26 2010-04-02 주식회사 중앙백신연구소 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
WO2011150413A1 (en) 2010-05-28 2011-12-01 Mount Sinai School Of Medicine Antiviral compounds and uses thereof
CA2850597A1 (en) * 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
EP2952209B1 (en) 2014-06-04 2018-03-28 Alfasigma S.p.A. Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
EP2952180B1 (en) 2014-06-04 2017-01-25 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
EP3120842A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
KR20170039456A (ko) 2015-10-01 2017-04-11 동아대학교 산학협력단 오동나무로부터 추출한 ｃ-제라닐플라보노이드계 물질을 포함하는 인플루엔자 예방 및 치료용 약학 조성물
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CN108893558B (zh) * 2018-05-24 2022-04-05 江苏海宏制药有限公司 一种桑木液原液抗病毒实验方法以及装置
EP4132277B1 (en) * 2020-04-05 2025-11-26 Mong, Michael Systems and methods for treating coronavirus
WO2026044308A1 (en) 2024-08-26 2026-03-05 Medizinische Universität Wien Treatment and prevention of diseases caused by influenza virus with 3,3',4,4',5,5'-hexahydroxy-trans-stilbene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2778337B1 (fr) 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
DE60015568D1 (de) * 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür

Also Published As

Publication number Publication date
JP2006507295A (ja) 2006-03-02
TW200501935A (en) 2005-01-16
TWI337863B (en) 2011-03-01
PL217628B1 (pl) 2014-08-29
JP4589118B2 (ja) 2010-12-01
KR20050071627A (ko) 2005-07-07
US20050239906A1 (en) 2005-10-27
CA2504872C (en) 2011-07-05
AR041891A1 (es) 2005-06-01
CY1107302T1 (el) 2012-11-21
AU2003279551A1 (en) 2004-06-07
US8431617B2 (en) 2013-04-30
EP1567137A1 (en) 2005-08-31
ATE381929T1 (de) 2008-01-15
PT1567137E (pt) 2008-02-19
CA2504872A1 (en) 2004-05-21
ES2295660T3 (es) 2008-04-16
PL377557A1 (pl) 2006-02-06
WO2004041260A1 (en) 2004-05-21
EP1567137B1 (en) 2007-12-26
ITRM20020562A1 (it) 2004-05-07
DE60318327D1 (de) 2008-02-07
MXPA05004628A (es) 2005-09-08
DK1567137T3 (da) 2008-04-28
KR101060331B1 (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
DE60318327T2 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
Qin et al. Anti-osteoporosis effects of osteoking via reducing reactive oxygen species
Son et al. Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia
Serkedjieva et al. In vitro anti-influenza virus activity of a plant preparation from Geranium sanguineum L.
EP2249866B1 (de) Verwendung eines acetylsalicylsäuresalzes zur behandlung viraler infektionen
US20220241325A1 (en) Antioxidant and antiviral compositions and methods
EP1599194B1 (de) Verwendung von acetylsalizilsäure zur prophylaxe und/oder therapie von viruserkrankungen
EP1699444A2 (de) Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
US6653344B2 (en) Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for treatment of neurodegenerative disease
Golovacheva et al. The Effect of Drugs with α-Glutamyl–Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro
Perfetto et al. In vitro antiviral and immunomodulatory activity of arbidol and structurally related derivatives in herpes simplex virus type 1-infected human keratinocytes (HaCat)
Dikmen et al. Neuritogenic activity of epigallocatechin gallate and curcumin combination on rat adrenal pheochromocytoma cells
JPH01233226A (ja) 抗ウイルス薬剤の製造への乳蛋白の利用
Valero et al. Melatonin Decreases Nitric oxide Production, Inducible Nitric oxide Synthase Expression and Lipid Peroxidation Induced by Venezuelan Encephalitis Equine Virus in Neuroblastoma Cell Cultures: Neurochem. Res.
CN117442616A (zh) Leukadherin-1在制备预防和/或治疗SARS-CoV-2感染的药物中的应用
WO2010003528A1 (de) Dimethylfumarat enthaltendes arzneimittel zur behandlung einer durch parasiten verursachten krankheit
WO2009103821A2 (de) Mittel zur behandlung von virusinfektionen
Bouaziz et al. Nitrate Provoked Kidney Toxicity and DNA Impairment in Adult Rats: Alleviation by Hyparrhenia hirta.
EP1406607B1 (de) Verwendung einer antiviralen verbindungsklasse (dithiocarbamat-verbindungen) zur herstellung eines mittels zur behandlung bzw. prävention einer virusinfektion im respiratorischen trakt
KR101023400B1 (ko) 상처 치료 또는 상처 치료 촉진용 약학 조성물
Markevičius et al. Effects of Exogenous SARS-CoV-2 S1 Protein and mRNA Vaccines on Mixed Neuronal–Glial Cell Cultures
Silva et al. The role of antiparasitc drugs and steroids in Covid-19 treatment
DE19514694A1 (de) Breitspektrum-Antiinfektivamittel
Kiran Aqil et al. In vitro antiviral activity of Nigella sativa against peste des petits ruminants (PPR) virus.
WO2015055623A1 (de) Zusammensetzung zur immunmodulation

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: GARACI, ENRICO, I-00040 POMEZIA, IT

Inventor name: PALAMARA, ANNA T., I-00040 POMEZIA, IT

8364 No opposition during term of opposition